Filgotinib Demonstrates Favorable Safety in Pooled Analysis of Phase III Studies in Patients With Rheumatoid Arthritis

November 8-13, 2019; Atlanta, Georgia
Results of this pooled analysis of 3 randomized, controlled phase III trials show filgotinib to be well tolerated, with no new safety signals, and low rates of MACE/VTE.
Format: Microsoft PowerPoint (.ppt)
File Size: 192 KB
Released: November 18, 2019


Provided by the Annenberg Center for Health Sciences at Eisenhower

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Supported by educational grants from
Gilead Sciences
Mallinckrodt Pharmaceuticals

Related Content

Results from subgroup analysis analyzing the efficacy, safety of dupilumab with or without concomitant TCS in patients with erythrodermic AD, from CCO

Released: July 27, 2020

Efficacy, safety of baricitinib in patients with 1 or more atopic comorbidity at baseline in BREEZE-AD1 and BREEZE-AD2, from CCO

Released: July 27, 2020

Effect of withdrawal and retreatment with upadacitinib during an interim analysis of the 88-week phase 2b trial, from CCO

Released: July 27, 2020

Efficacy, safety of once-daily oral abrocitinib 200 mg and 100 mg vs placebo in patients aged ≥12 years with moderate to severe AD; atopic dermatitis conference coverage from CCO

Released: July 20, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?